Navigation Links
Oxygen Biotherapeutics, Inc. to Present at Investor Conferences in Zurich
Date:9/22/2009

DURHAM, N.C., Sept. 22 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that company chairman and CEO, Chris Stern, will present at an investor conferences in Zurich on Sept. 30, 2009.

The presentation will be at the Zurich Airport Radisson Hotel and is scheduled for 7:00 p.m. The German language presentation will not be webcast but will be open to interested investors.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte((R))) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Posts Blog by CEO Chris Stern on Proposed Reverse Split
2. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
3. Car Seats Can Limit Kids Oxygen Supplies
4. Pitt researchers harness carbon nanomaterials for drug delivery systems, oxygen sensors
5. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
6. Injections May Benefit Oxygen-Deprived Newborns
7. New groundbreaking treatment for oxygen-deprived newborns
8. Global Health Trax, Inc. Announces New Marketing Campaign for Oxygen Elements Max Product
9. Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury
10. Northwest Hospital Introduces Hyperbaric Oxygen Therapy
11. Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 24, 2017 , ... symplrTM, a leading provider of software ... Kyle Allain has joined the company as Vice President and General Manager of ... payor and managed care solutions. , A seasoned executive with more than ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management ... , Rod has been at the forefront of Gardant since it was founded in ... has overseen the opening of more than 40 new senior living communities. With his ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform ... difficult for lab operators and management to assess these processes with a critical ... or unnecessary actions. , Created with the help of both internal and ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of ... Chairman of the Board of Directors for CONTACT USA, and former member of the ...
(Date:4/24/2017)... Greensboro, NC and Seattle, WA (PRWEB) , ... ... ... currently utilized by 75+ leading lifestyle brands, work wear distributors and International relief ... diseases they can carry. The company also offers lifestyle and work wear collections ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)... , April 18, 2017  Spero Therapeutics, LLC, ... the treatment of bacterial infections, will present preclinical data ... treatment of multidrug resistant (MDR) Gram-negative infections at the ... (ECCMID) April 22-25, 2017 in Vienna, Austria ... ...
Breaking Medicine Technology: